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Purpose: To determine the risk factors of delayed recanalization of isolated calf vein thrombosis (CVT). Methods: One hun-
dred fifty limbs of 110 patients with CVT between September 2007 and April 2010 were enrolled. We used ultrasonography 
for the diagnosis and follow-up examinations of CVT. We calculated recanalization rates at 1 and 3 months after initial diag-
nosis and analyzed the risk factors associated with delayed recanalization of CVT. Results: CVTs were located in the muscu-
lar calf vein in 110 (73.3%), in the deep calf vein in 18 (12%), and in both in 22 cases (14.7%). Among all CVTs, 94 limbs (63%) 
were symptomatic. Major risk factors for CVT were orthopedic surgery (87.3%), malignancy (21.3%), and immobilization 
(15.3%). Sixty-seven patients (60.9%) were treated with oral anticoagulation therapy, while 43 patients by low molecular 
weight heparin (n = 19) or by conservative methods including elastic compression stockings and ambulation (n = 21). The cu-
mulative recanalization rate at 1 and 3 months was 23% and 82% and it was significantly higher in patients who underwent 
oral anticoagulation therapy compared with patients without oral anticoagulation therapy (84% vs. 65%, P = 0.008 by 
log-rank test). Malignancy (odds ratio [OR], 2.789; P = 0.043) and immobilization (OR, 4.191; P = 0.029) were independent risk 
factors for delayed recanalization of CVT and oral anticoagulation (OR, 0.300; P = 0.020) was an independent factor in pro-
moting recanalization in multivariate analysis. Conclusion: For patients with isolated CVT, no oral anticoagulation resulted 
in higher rates of delayed recanalization compared to oral anticoagulation treatment. Immobilization and having malig-
nancy were independent risk factors for delayed recanalization.
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INTRODUCTION
Isolated calf vein thrombosis (CVT) is comprised of 
muscular (soleal and gastrocnemius sinus) and deep 
(posterior tibial, anterior tibial, and peroneal veins) ve-
nous thrombosis (DVT) in the calf. Unlike proximal DVT, 
the clinical importance of CVT has often been under-
estimated. CVTs are more frequently detected and its clin-
ical significance has been discussed since ultrasonography 
(US) was first used for the diagnosis of DVT [1,2]. The Delayed recanalization of isolated CVT
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prevalence of CVT is 5 to 12% in patients with sympto-
matic venous thrombosis [3]. CVT may develop in 15% of 
asymptomatic patients after hip and knee surgery, and in 
45% of patients after coronary bypass grafting [4-6].
For the treatment of CVT, international guidelines rec-
ommend three months of oral anticoagulation therapy at 
the full therapeutic dosage [7]. However, in clinical prac-
tice, we have encountered frequent resolution of CVT after 
short-duration anticoagulation therapy, as well as cases of 
spontaneous resolution. Therefore, questions have been 
raised regarding the optimal duration of anticoagulation 
for patients with CVT and risk factors for delayed recanali-
zation after anticoagulation.
The purposes of this study were to observe recanaliza-
tion rates in CVT patients at 1 and 3 months, and to de-
termine the risk factors related to delayed recanalization 
of CVT.
METHODS
Approval was obtained from our Institutional Review 
Board to review medical records and the results of imag-
ing studies. We selected CVT patients diagnosed and 
treated between September 2007 and April 2010 from the 
patient database of the vascular lab. Asymptomatic pa-
tients were diagnosed as a surveillance protocol in ortho-
pedic surgery or neurosurgery for the high risk patients. 
Only the patients who had follow-up duplex US (iU 22, 
Phillips, Best, The Netherlands; ACUSON Antares, 
Simens AG, Munich, Germany) for 1 month or longer were 
included in this study. 
Patients with concurrent proximal DVT or a prior his-
tory of unilateral leg swelling were excluded from this 
study. Diagnoses of acute CVT were made based on du-
plex US findings and diagnosis of pulmonary embolism 
(PE) was made with CT scan. All duplex US examinations 
were performed by three experienced registered vascular 
technologists. Veins in both lower extremities were exam-
ined with duplex US from the inferior vena cava to the calf 
veins following a standardized method. In brief, compres-
sibility, presence of venous flow, and presence of intra-
venous echoic material in the anterior tibial, posterior ti-
bial, and peroneal veins, as well as the soleal and gastro-
cnemius veins, were examined in legs in a dependent 
position.
After detection of CVT, all the patients were recom-
mended to prescribe anticoagulation therapy if possible, 
except the patients with contraindication to anti-
coagulation or risk of bleeding. For the purpose of anti-
coagulation, nineteen patients (17.3%) were treated only 
with low-molecular-weight heparin (LMWH) (median, 5 
days; range, 1 to 5) and 67 patients (60.9%) were treated 
with LMWH and overlapped sufficiently and followed by 
oral anticoagulants (warfarin) for 37.0 days (range, 11 to 
268 days) targeting 2 to 3 international normalized ratio of 
prothrombin time. Fifteen patients (13.6%) were pre-
scribed oral anticoagulants for longer than six months due 
to concurrent PE or persistence of major risk factors for ve-
nous thromboembolism (VTE). Twenty-four patients (21.8%) 
who were incompliant to our prescription of anticoa-
gulation therapy were managed conservatively with elas-
tic compression stockings and leg elevation. Finally, oral 
anticoagulation therapy was performed 64% (60 of 94 
limbs) in symptomatic patients and 61% (34 of 56 limbs) in 
asymptomatic patients, respectively. 
Wearing elastic compression stockings was recom-
mended for all patients. Early ambulation was also en-
couraged if possible. When follow-up duplex US at one 
month showed persistence or incomplete resolution of 
CVT, anticoagulation therapy was extended for two more 
months or more. Duplex US examinations were per-
formed at 1 and 3 months after diagnosis of CVT for all 
patients.
To determine the risk factors of delayed recanalization 
of the calf vein, the coexisting risk factors of DVT (recent 
surgery, trauma, lengthy air or car travel, immobilization, 
coexisting cancer, use of oral contraceptives), location of 
CVT (muscular vs. tibial and peroneal vein), presence of 
calf pain or swelling, oral anticoagulation or not were in-
cluded in the statistical analysis. We compared recanaliza-
tion rate in 3-month follow-up duplex scan between oral 
anticoagulation with warfarin group (n = 67) and no oral 
anticoagulation group (n = 43) using the Kaplan-Meier 
method. In addition, we tried to identify the risk factors of 
delayed recanlaization of CVT.Yang Jin Park, et al.
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Characteristic
Anticoagulation 
(n = 67, 61%)
No anticoagulation 
(n = 43, 39%)
P-value
Female gender 53 (79.1) 34 (79.1) 1.000
Age (yr) 0.356
  Mean ± SD
  Median (interquartile range)
63.8 ± 11.7
  65 (60-70)
62.3 ± 10.8
  65 (56-70)
Coexisting risk factors of deep venous thrombosis
  Immobilization  8 (11.9)  8 (18.6) 0.333
  Surgery 63 (94.0) 32 (74.4) 0.003
  Trauma 4 (6.0) 2 (4.7) 1.000
  Cancer 13 (19.4) 10 (23.3) 0.628
  Oral contraceptives 1 (1.5) 0 (0) 1.000
Pulmonary embolism 4 (6.0) 2 (4.7) 1.000
Values are presented as number (%) or mean ± SD.
Table 1. Patients characteristics and risk factors of deep vein thrombosis
Characteristic
No. of limbs with calf vein 
thrombosis
P-value
Anticoagualtion
(n = 94)
No 
anticoagulation 
(n = 56)
Muscular vein 
 thrombosis
80 (85.1) 52 (92.9)
 Soleal  79 (84.0) 52 (92.9) 0.116
 Gastrocnemius  1 (1.1)   0 (0) 1.000
Deep vein thrombosis 28 (29.8) 12 (21.4)
 Anterior /
    posterior tibial
14 (14.9)   8 (14.3) 0.919
 Peroneal 20 (21.3)   9 (16.1) 0.435
Both muscular and 
 deep vein
14 (14.9)   8 (14.3)
Symptom/sign 60 (63.8) 34 (60.7) 0.703
 Calf pain 50 (53.2) 20 (35.7) 0.038
 Calf swelling 31 (33.0) 26 (46.4) 0.101
Values are presented as number (%).
Table 2. Clinical characteristics of calf vein thrombosis Statistics
Data analyses were performed using IBM SPSS ver. 18.0 
(IBM Co., New York, NY, USA). Continuous variables 
were described as mean ± SD, and the Student’s t-test was 
used for comparisons. Categorical variables were de-
scribed as number and percentage and chi-Square test was 
used for comparison. The recanalization rates of CVT at 1 
and 3 months were calculated using the Kaplan-Meier 
method. For the assessment of risk factors of delayed re-
canalization of CVT, a simple logistic regression test in 
univariate analysis and binary logistic regression test in 
multivariate analysis were used. P-values less than 0.05 
were considered statistically significant.
RESULTS
During the study period, data for 292 limbs with iso-
lated CVT in 213 patients were collected at a single 
institute. One hundred fifty limbs (51.4%) in 110 patients 
(87 females; mean age, 63.4 ± 11.2 years; range, 23 to 80 
years) were available to follow-up examinations and in-
cluded in this study.
A comparison of patient demographics and coexisting 
risk factors for VTE between patients who received anti-
coagulation and those who did not is shown in Table 1. 
There were no significant differences in the frequencies of 
risk factors between the two groups except for cases in 
which the patient had a history of recent surgery, which 
were more common in anticoagulation group than in the 
no anticoagulation group (94% vs. 74.4%, P = 0.003). The 
most common coexisting risk factor for DVT was recent 
surgery, which occurred in 95 patients (86.4%), of which 
orthopedic surgery (knee or hip replacement arthro-
plasty) was the most prevalent (77 patients, 70%).
The distributions of CVT and symptoms/signs are 
shown in Table 2. Thrombosis was located in the unilateral 
calf in 70 patients (64%) and was bilateral in 40 patients 
(36%). One hundred thirty-two thromboses (88%) in-
volved the muscular veins (soleal sinus, 131 limbs; gastro-Delayed recanalization of isolated CVT
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Fig. 1. Comparison of recanalization rates (by Kaplan-Meyer 
calculation) between anticoagulated versus non-anticoagulated 
groups of calf vein thrombosis patients.
P-value Odds ratio
95% Confidence 
interval
Lower Upper
Female gender 0.148 0.510 0.205 1.271
Age 0.081 0.970 0.938 1.004
Recent surgery 0.0057 0.233 0.083 0.655
Immobilization 0.0012 4.977 1.887 13.128
Cancer 0.0318 2.701 1.090 6.689
Oral   anticoagulation 0.0034 0.273 0.115 0.651
Table 3. Univariate analysis for delayed recanalization of calf vein 
thrombosis
P-value Odds ratio
95% Confidence 
interval
Lower Upper
Female gender 0.933 0.997 0.957 1.038
Age 0.867 0.997 0.957 1.038
Recent surgery 0.414 0.585 0.162 2.117
Immobilization 0.029 4.191 1.161 15.127
Cancer 0.043 2.789 1.031 7.548
Oral anticoagulation 0.020 0.300 0.109 0.828
Table 4. Multivariate analysis for delayed recanalization of calf vein
thrombosis
cnemius vein, 1 limb), while deep vein were involved in 40 
limbs (27%) (tibial vein, 22 limbs; peroneal vein, 29 limbs), 
and both muscular and deep calf veins were involved in 22 
limbs (14.7%). There was no significant difference in the 
distribution of CVT between the anticoagulation and no 
anticoagulation groups. CVT was symptomatic in 94 limbs 
(62.7%) and calf pain was more prevalent in the anti-
coagulation group than in the no anticoagulation group 
(53.2% vs. 35.7%, P = 0.038). Symptomatic PE developed in 
6 (5.5%) of the CVT patients.
Follow-up examinations with duplex US of CVT were 
performed in all patients at 1 month and in 128 limbs 
(85.3%) of 92 patients (83.6%) at 3 months. During the fol-
low-up periods of 3 months, we observed complete recan-
alization of the calf vein in 94 limbs (62.7%), partial recan-
alization in 29 (19.3%), and no recanalization in 25 limbs 
(16.7) with CVT on duplex US. As shown in Fig. 1, accord-
ing to Kaplan-Meier estimates, the recanalization rate of 
CVT was significantly higher in the oral anticoagulation 
group than in the no oral anticoagulation group (84% vs. 
64.8%, P = 0.008) (Fig. 1). However, no significant differ-
ence was detected in the recanalization rate between mus-
cular CVT and deep CVT (81% vs. 85%, P = 0.564).
According to our univariate risk factor analysis for re-
canalization of CVT, immobilization, coexisting cancer, re-
cent surgery, and anticoagulation therapy significantly in-
fluenced the recanalization of CVT (Table 3). Multivariate 
analysis revealed that immobilization (P = 0.029; OR, 
4.191) and coexisting cancer (P = 0.043; OR, 2.789) were in-
dependent risk factors associated with delayed recanali-
zation of CVT, whereas anticoagulation therapy (P = 0.020; 
OR, 0.300) was likely to promote the recanalization of CVT 
(Table 4). 
Among 110 CVT patients, progression to proximal DVT 
and PE was detected in 1 (0.9%) of limbs and 6 (5.5%) of pa-
tients, respectively. During the follow-up period, three pa-
tients (2.7%) died of cancer or gastrointestinal bleeding, 
however there was no recurrence of CVT or PE during the 
follow-up period. 
DISCUSSION
Isolated CVT is a common finding but was often ignor-
ed until US was used for the diagnosis of venous 
thrombosis. Incidence of CVT is known to be 100 times 
higher than that of symptomatic DVT [8,9]. It is assumed 
that most of these small thrombi resolve completely via 
natural mechanisms of thrombolysis, although some of Yang Jin Park, et al.
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them progress to symptomatic or proximal DVT [10]. The 
clinical importance of CVT arises from its potential risk of 
progression to the proximal vein and risk of PE. Some cas-
es of CVT have been known to progress into the deep veins 
as well as to symptomatic PE [11,12]. MacDonald et al. [13] 
reported on the progression rate of isolated CVT to the lev-
e l  o f  a d j a c e n t  t i b i a l  o r  p e r o n e a l  v e i n s  o r  h i g h e r  i n  2 2  
(16.3%) of the 135 limbs studied and 4 (3%) extensions to 
the popliteal vein during a 3-month follow-up in a cohort 
followed by duplex US without any treatment. Schwarz et 
al. [12] conducted a prospective nonrandomized study in-
cluding 84 isolated muscular CVTs and showed a sig-
nificantly higher rate of progression to the deep calf veins 
(25%) in the 32 patients (38 %) who had not undergone an-
ticoagulation therapy [12]. These two studies showed that 
the proximal extension or progression rates of CVT were 
higher in patients who were not treated with anti-
coagulation therapy, and the extension occurred early af-
ter the diagnosis in most of the patients. Gillet et al. [14] re-
ported no extension or recurrence rates of CVT at 3 
months, but a high (18.8%) rate of VTE recurrence in 
symptomatic CVT patients in a midterm follow-up (mean, 
26.7 months) [14]. In the present study, we observed very 
low rate (0.9%) of CVT progression to the deep (tibial) 
vein, and no patient showed recurrent VTE or sympto-
matic PE during the follow-up period. Previous research 
regarding the relationship between CVT and PE has pro-
ven equivocal. Although Gillet et al. [14] reported on the 
development of PE in 7% of cases of isolated CVT, others 
reported 13 to 15% fatal PE in patients with asymptomatic 
isolated CVT after surgery [15]. Spontaneous resolution of 
CVT is known to occur, with a 50% reduction of signs and 
symptoms at one month and complete resolution of symp-
tom or signs by one year in most patients [16]. However, 
post-thrombotic manifestations develop in 4% of patients, 
and valvular incompetence occurs in 20 to 24% of patients 
[17]. MacDonald et al. [13] reported that complete recanal-
ization of the calf vein at 1 and 3 months occurred in 20.7% 
and 44.6% of cases of muscular CVT, respectively. In our 
study, overall recanalization rates at 1 and 3 months were 
23% and 82%, respectively. There was a significant differ-
ence in the recanalization rates between the anticoa-
gulation group and the no anticoagulation group (84% vs. 
64.8, P = 0.008). Furthermore, oral anticoagulation therapy 
was one of the independent factors responsible for the pro-
motion of recanalization of CVT, according to the findings 
of multivariate analysis. 
Although the American College of Chest Physicians 
guidelines [7] recommend 3 months of anticoagulation 
therapy for patients with CVT, many physicians and vas-
cular surgeons stop anticoagulation earlier, when the calf 
vein thrombus and related symptom have disappeared. 
By understanding the risk factors of delayed recanaliza-
tion, we can develop a more detailed therapeutic guide-
line for determining optimal durations of anticoagulation 
for specific groups of CVT patients to avoid unnecessary 
anticoagulation therapy.
Seventy-seven percent of CVT patients in our study re-
ceived immediate anticoagulation therapy after diagnosis 
of CVT and were treated for a median of 37 days. Among 
the patients group, thrombus extension occurred in one 
limb (0.9%) from the muscular vein to the tibial vein.
There were no known risk factors associated with de-
layed recanalization of CVT. In the present study, we 
found that coexisting cancer or immobilization had sig-
nificantly lower recanalization rates, and longer anti-
coagulation therapy is required for such patients. 
This study has limitations including study design that 
was not randomized and therefore may suffer from se-
lection bias. Second, the maximum 3-month follow-up in-
terval is not sufficient to observe the long-term complica-
tions of CVT or recurrence of venous thrombosis. Third, 
we could not check consistently the hypercoagulability 
state of the patients like as protein C or S and don’t have 
enough data to analyze because most of the patients were 
in other department like as orthopedic surgery.
In conclusion, for patients with isolated CVT, no oral an-
ticoagulation resulted in a higher rate of delayed recanali-
zation compared with oral anticoagulation therapy. Risk 
factors associated with delayed recanalization of the calf 
veins were coexisting cancer and recent long-term im-
mobilization, and CVT in patients with such risk factors 
are more likely to require longer anticoagulation than in 
patients with other risk factors. Delayed recanalization of isolated CVT
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